Fibroblast activating protein-α expression in squamous cell carcinoma of the esophagus in primary and irradiated tumors: the use of archival FFPE material for molecular techniques

Renata Tabola,¹ Magdalena Zaremba-Czogalla,¹ Dagnara Baczynska,² Roberto Ciocchi,³ Kamila Stach,⁴ Krzysztof Grabowski,¹ Katarzyna Augoff⁵
¹Department of Gastrointestinal and General Surgery, Medical University of Wroclaw, Poland
²Department of Molecular Techniques, Medical University of Wroclaw, Poland
³Department of General and Oncological Surgery, University of Perugia, Italy
⁴Department of Biochemistry, Medical University of Wroclaw, Poland

Abstract

There are numerous reports suggesting that fibroblast activating protein-α (FAP-α) plays an important role in invasion of various tumor types. We studied the expression pattern of FAP-α in esophageal squamous cell carcinoma (ESCC) patients who had not been treated primarily and those who had received neoadjuvant radiochemotherapy. Our goal was to establish whether readily available tissue specimens fixed in formalin and stored in paraffin blocks for years might still be a source of FAP-α RNA for PCR analysis. The study included 20 patients divided into two groups, 10 patients in each group. We evaluated the expression of FAP-α by PCR techniques in fresh frozen and in paraffin-embedded tissues, and compared it to the expression in non-cancer tissues. To detect the protein expression level of FAP-α in paraffin-embedded tissues we used chromogenic immunohistochemical (IHC) staining. Data were analyzed by t-test or the nonparametric Wilcoxon matched pair test using Statistica 12.5 software. We observed an increased level of the FAP-α gene and protein expression in cancer tissues when compared with their corresponding normal tissues. However, statistically significant differences were found only in the group of patients untreated before surgery. RNA extracted from paraffin-embedded tissue sections had very low quality, especially in the context of degradation. FAP-α remains a highly altered participant of a complex microenvironment in esophageal squamous cell carcinoma, and its role in cell signaling requires further study. In this paper, we conclude that the use of a regular RT-PCR method for diagnostic purposes, which we have presented in an earlier paper, can be as good as qRT-PCR. Also, immunohistochemistry proved to be very useful and the only reliable method that can be used on formalin-fixed, paraffin-embedded tissues stored long term.

Introduction

In recent years, attention has been paid to the close association between cancer and its microenvironment considering tumor growth, potential for invasion and metastasis. There are many reports suggesting that fibroblast activating protein-α (FAP-α) plays an important role in invasion of many tumor types. FAP-α is a serine protease that belongs to the family of transmembrane proteases, to which also dipeptidyl peptidase IV (DPPIV) belongs. They are grouped on the basis of their proteolytic activity, structure and behavior in their natural environment.¹ They share a unique ability to cleave the post proline bond that is usually resistant to degradation. FAP-α exists on the cell surface and in a soluble circulating form in the blood.¹ So far, little is known about the normal physiological role of either its cellular or circulating form. The cellular form of FAP-α possesses two lytic activities.² It is best known for the endopeptidase activity. Gelatin is FAP’s best explored substrate, and the gelatinase activity can be used to monitor its proteolytic activity. So FAP-α is involved in remodeling of extracellular matrix (ECM) with native and denatured collagens (gelatin). FAP-α is expressed as an active protease with no need for zymogen activation.³ The biological significance of FAP-α cleavage of gelatinase or collagen type I is still not known.⁴,⁵ Peptide hormones such as neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are natural substrates for FAP-α dipeptidyl peptidase activity. The cleavage of peptide hormones involves FAP-α in influencing the tissue microenvironment.⁶ There is growing interest in FAP-α involvement in cell signaling. FAP-α is well known for its presence in stromal fibroblasts, called cancer-associated fibroblasts (CAFs), found in over 90% of epithelial tumors. However, tumor cells expressing FAP-α have been shown to possess either increased or decreased invasive behavior.⁷,⁸ Some studies have shown that FAP-α overexpression on tumor cells rather than on reactive fibroblasts was associated with more aggressive behavior of the tumor.⁹ Still, its expression is observed nearly exclusively in tumor stroma.¹⁰ Esophageal squamous cell carcinoma (ESCC) is a cancer with highly aggressive behavior and a 5-year survival rate of only 10%.¹¹ The stroma associated with epithelial carcinomas, to which esophageal cancer belongs, remains a significant portion of its mass. It has been shown that the tumor is dependent on the reactive stroma for nutritional support, survival and progression. The stroma undergoes morphological alterations when attached to transformed epithelium: it recruits reactive fibroblasts, increases secretion of growth factors and proteases, and induces angiogenesis, to mention only a few activities.¹²,¹³ CAFs are essential to regulate the network of interactions occurring among the malignant epithelial cells, ECM and various noncancerous cells that are found in tumor surroundings, including endothelial, adipose, inflammatory and immune cells, and yet they remain an important part of the tumor milieu. FAP-α expression has been most extensively studied in CAFs associated with breast cancer and has relatively seldom been discussed in esophageal squamous cell carcinoma.¹⁴ Therefore, we studied the expression pat-
tern of FAP-α in esophageal squamous cell carcinoma patients who had not been treated primarily. We evaluated expression of FAP-α by immunohistochemistry and qRT-PCR in fresh frozen tissues and in paraffin-embedded tissues, and compared it to the expression in non-cancer tissue. Our goal was to establish whether readily available tissue specimens fixed in formalin and stored for years might still be used as a source not only for IHC staining but also for RNA analysis. We evaluated protein expression levels of FAP-α using immunohistochemistry, and the results were compared to data obtained by PCR techniques. Finally, we evaluated the FAP-α level alterations in a group of patients who underwent neoadjuvant chemoradiotherapy.

Materials and Methods

Patients and samples

The study included 20 patients (14 men and 6 women) divided into two groups, 10 patients in each group. Mean age of the patients was 59 (range: 45-74 years). All the patients were treated at the Department of Gastrointestinal and General Surgery of Wroclaw Medical University (Poland) between 2006-2007 and 2015-2016 and had histologically confirmed primary ESCC. The first group included those patients who had received no previous treatment before surgery of the esophagus. In this group, all individuals had tumors diagnosed as pT2 or pT3, N0-N2 and M0 according to the TNM classification, and the second group had tumors diagnosed as pT2 or pT3, N0-N3 and M0 according to the pTNM classification (applied according to the guidelines from the American Joint Committee on Cancer staging manual) and received neoadjuvant chemoradiotherapy before surgery. As a result of the treatment, six of these patients (60%) were cancer negative on histopathological analysis after esophagectomy. None of the patients had any other serious diseases. The patients were informed about the potential use for research purposes of their surgically resected tissues. The study was approved by the ethics committee. The study was approved by the university committee for internal grants (grant number ST-879). The committee decided it did not require special authorization by the University Ethical Committee because our examinations were carried out in parallel with the histopathological examinations on the material that was used for standard procedures and had already been surgically removed for curative resection.

All the analyzed esophageal cancer specimens obtained during surgery were paired with nonmalignant tissue samples taken from the same individuals from the distal area of the esophagus, located 5 to 10 cm away from macroscopic tumor changes. Using histological examinations control samples were confirmed to be disease free (R0). Tissue samples were immediately put on ice, weighed, divided into pieces, snap-frozen in liquid nitrogen and kept at -80°C until further use. For immunohistochemical studies the tissue samples were fixed (for up to 7 days) in 10% formaldehyde solution in PBS (1:10 v/v) and then embedded in paraffin. RNA isolation from frozen tissues and formalin-fixed, paraffin-embedded tissue blocks, 30-50 mg fragments of frozen tissue were placed in a RLT lysis buffer (supplemented freshly with B-mercaptoethanol) supplied with the RNeasy Mini kit (Qiagen). Tissue was allowed to thaw, homogenized by scissors and processed further according to the manufacturer’s instructions. RNA was eluted in 50 μL of RNase-free water. Total RNA from formalin-fixed, paraffin-embedded (FFPE) tissues was extracted using the RNeasy FFPE Kit (Qiagen). FFPE blocks were cut into sections and subjected to xylene/ethanol deparaffinization. Deparaffinized samples were incubated in lysis buffer supplemented with proteinase K (56°C for 15 min, then at 80°C for 15 min). During the isolation, genomic DNA was eliminated by DNase I treatment. RNA was eluted from the column in a volume of 30 μL of RNase-free water. Quantity and quality of obtained RNA were analyzed by NanoDrop measurements at OD of 260 nm, and A260/A280. Aliquoted total RNA samples were stored at -80°C until further use.

qRT-PCR

The cDNA used as a template for real-time PCR was produced using the SuperScript III First Strand Synthesis System for the RT-PCR Kit (Invitrogen by Life Technologies, Carlsbad, CA, USA). Total RNA samples (50 ng/mL) were reverse transcribed to cDNA according to the manufacturer’s protocol. cDNA synthesis reactions were primed using random hexamers (10 min at 25°C, followed by 50 min at 50°C) and the reaction was terminated at 85°C for 5 min. After cDNA synthesis, the RNA template was removed by digestion with RNase H (20 min at 37°C). cDNA was stored at -80°C and then used in the PCR reaction (4 μL of cDNA mixture per 20 μL reaction). Quantitative real-time PCR primer pairs were purchased from Sino Biological Inc. (Beijing, China), designed by using SBI’s proprietary primer design algorithm. To avoid genomic DNA amplification, at least one primer crosses the junction of exons. GAPDH (glyceraldehyde-3-phosphate dehydrogenase), which was chosen as a reference gene, and FAP-α transcripts were detected in the samples by presence of 108-bp or 97-bp amplification products, respectively.

qRT-PCR was performed using iTaq Universal SYBR Green Supermix (Bio-Rad, Hercules, CA, USA) in a reaction mixture containing SYBR Green I dye and gene-specific primer pairs at the final concentration 0.8 nM. Reactions were conducted on the 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA); thermal cycling conditions were as follows: polymerase activation and DNA denaturation at 95°C, followed by 40 cycles of 2 s denaturation at 95°C, 20 s annealing at 60°C, and 20 s extension at 60°C. For each of the RNA extractions, PCR reactions were done in duplicate, and a negative control (water) was included in each run. Small, nonspecific primer-dimers in the negative control runs were obtained. FAP-α mRNA level was normalized to the arithmetic mean of the housekeeping gene level and analyzed using the 2^(-ΔΔCT) method.
using ImageJ 1.50a software. The fold change value was calculated as the ratio of the difference between mean gray values obtained for control and cancer tissues.

**Statistical analysis**

The results are expressed as the mean (±SD) or the median (range). Data were analyzed by *t*-test or the nonparametric Wilcoxon matched pair test using Statistica 12.5 software. Values of *P*<0.05 were considered statistically significant.

**Results**

Real-time PCR analysis of FAP-α using RNA extracted from fresh frozen tissues.

The results from individual patient data obtained by the qRT-PCR assays for the treated and untreated group are shown in Figure 1 A,B. qRT-PCR data for each sample are presented as relative gene expression calculated by the $2^{-\Delta\Delta CT}$ method.

We observed an increased level of FAP-α gene expression in cancer tissues when compared with their corresponding normal tissues in both groups. However, statistically significant differences were found only in the group of patients untreated before surgery. For these patients, the mean value of FAP-α overexpression was 2.3-fold higher in tumor versus control tissues (Table 1), FAP-α was overexpressed at least 2-fold in 6 (60%) of all examined patients, and the highest overexpression was about 12-fold (Figure 1). In the group of patients who underwent neoadjuvant therapy before surgery changes were not statistically significant (Table 1).

**Real-time PCR analysis of FAP-α using RNA extracted from formalin-fixed, paraffin-embedded tissues**

To determine the usefulness of FFPE samples stored in the archives of Wroclaw Medical University as readily accessible historical material for FAP-α level molecular analysis, we isolated total RNA from such available material and performed real-time PCR. The selected FFPE samples were ten years old, prepared according to the pro-
tocols routinely used in our hospital. To verify the procedure efficiency, we used RNA isolated from freshly collected tissue derived from the same patient as references. As could be expected, RNA extracted from paraffin-embedded tissue sections had a very low quality, especially in the context of degradation. On the agarose gel the RNA could be seen as a low molecular weight smear, contrary to RNA prepared from fresh tissues (Figure 1C).

For detection of FAP-α mRNA we used the standard real-time PCR reaction procedure which was used by us before. Regrettably, in regards of FFPE samples the results were not reliable, whereas for RNA isolated from fresh material and frozen for 10 years before usage, we obtained data which were fully compatible with calculations made previously by using reverse transcription PCR reactions.21

Immunohistochemistry

To verify whether changes at the mRNA stage reflect alterations at the protein level, we prepared the immunohistochemical staining of paraffin-embedded tissue sections from previously untreated patients with antibody directed against fibroblast activation protein. The obtained results were in accordance with the molecular biology data and showed an increase in protein level of FAP-α in tumor tissues when compared to marginal nonmalignant tissues taken from the same patient from the distal area of the esophagus characterized by the absence of macroscopic tumor changes. Histologically, FAP-α expression was restricted mostly to the stroma. The immunostaining with antibody in controls, cancer-free samples, was either very weak or locally moderate (Figure 2). Quantitative analysis of IHC staining confirmed a statistically significant difference between controls and cancer tissues. The average value of fold change was 2.7, where fold change indicates the cancer-to-control ratio (Figure 3).

Discussion

FAP-α evaluation is relatively new and has been used mostly for research purposes. Overexpression of serine proteases, to which FAP-α belongs, has been associated with cancer invasion and metastasis, essentially in gastrointestinal cancers.1,22-24

In the study, we evaluated FAP-α expression and protein distribution in the tumor mass in comparison to cancer-free samples in esophageal squamous cell carcinoma patients who underwent resection

---

**Figure 2.** Examples of IHC staining patterns for FAP-α in the normal and tumorous tissues of the esophagus in three randomly chosen patients (P. I-III) untreated before surgery at a total magnification of 200x. Weak and locally moderate FAP-α immunoreactivity in normal epithelium (C, F, I). Strong FAP-α immunoreactivity in esophageal squamous cell carcinomas (A, B, D, E, G, H). Scale bars: 100 μm.

**Figure 3.** Quantification of IHC staining for FAP-α. Bar chart shows a statistically significant increase (average fold change of 2.7) in the intensity of staining in tumor tissues compared to normal tissues. The fold change indicates the ratio of mean gray values of normal to cancer tissues. Images are representative cases of IHC staining at a total magnification of 400x. They show the weakest (A) and the strongest (B) FAP-α immunoreactivity in esophageal normal and cancer tissues, respectively.
without preoperative treatment and after irradiation and chemotherapy. We also wanted to estimate the usefulness of FFPE samples stored in the archives of Wroclaw Medical University as readily accessible historical material for molecular analysis of FAP-α level. We observed statistically significant overexpression of FAP-α as measured by both protein and RNA levels in the tumor tissue of the patients who did not undergo previous treatment (P<0.005). However, we did not confirm these findings using real-time PCR methods on RNA extracted from formalin-fixed tissues, probably due to poor quality of the RNA we isolated from ten-year-old FFPE tissue specimens, fixed in 10% formalin. It is known that quality of the RNA extracted from paraffin-embedded tissue that undergoes chemical modifications and continues degradation over time can be low. The age and storage conditions including temperature and humidity of the tissue fixed in paraffin play a central role.25 According to the published data, the longer the paraffin samples are stored, the more severe is the degradation observed. It seems that the critical storage time is 3 years.26,27

FAP-α has been reported to be present in the tumor stroma of epithelial cancers including esophageal squamous cell carcinoma, essentially on CAFs, which contributed to tissue remodeling and invasiveness of the tumor by secreting proteases degrading the ECM and promoting the epithelial mesenchymal transition.15,24,26-31 This is in agreement with our findings on all the samples of the tumor tissues in patients who did not receive any previous treatment. In these patients, the mean value of overexpression of FAP-α was 2.3-fold higher than in resection margins proved to be free from neoplastic cells on histology. However, in the group after previous chemoradiation, our findings were more interesting. FAP-α was generally more highly expressed in the tumor tissue than in the resection margins, but it was not as strong as in tumors with no previous treatment: 2.3-fold versus 2.2-fold stronger. The difference between the tumor tissue and normal tissue taken from the resection margin was not statistically significant for this group (P>0.005). Even more important, FAP-α expression did not correlate with histological findings. In this group, almost all macroscopically abnormal tissues with the highest FAP-α level were cancer negative with negative lymph nodes on microscopic examination. Nevertheless, our observation is in agreement with Goscinski et al., who noted a significantly decreased FAP-α expression in irradiated patients.1 FAP-α possesses collagenolytic activity which may increase during tissue remodeling processes: granulation tissue in healing wounds occurring in the esophagus after irradiation, the intensity of which is multifactor and requires further studies. A meta-analysis by Liu et al. showed that poorer prognosis among patients with epithelial tumors was significantly higher if FAP-α was overexpressed by tumor cells rather than fibroblasts.34 Our results may support the theory. Sixty per cent of the tumors were negative for cancer cells after chemoradiotherapy, so we conclude that FAP-α attached to cancer cells decreased in this group of patients, but was still present in granulation tissue when the irradiated site was healing. The hypothesis requires further verification with a larger patient cohort. It is known that FAP-α expression takes place not only in cancer tissues, but also in response to pathologic situations such as fibrosis and inflammation.25,35 Cancer development and wound healing are dynamic processes that have several similarities. This phenomenon is clearly in accordance with our results. The presence of high levels of FAP-α in tissues free from cancer after neoadjuvant therapy suggests its participation in extracellular matrix remodeling in both cancer and wound healing.

We evaluated FAP-α expression with PCR techniques on formalin-fixed, paraffin-embedded samples and on fresh-frozen tissues and attempted to validate these two RNA sources. We concluded that it is not possible to use our formalin-fixed, paraffin-embedded tissue to evaluate FAP-α alpha expression level using molecular techniques. However, the qRT-PCR analysis confirmed data obtained by regular RT-PCR when we used RNA isolated from fresh-frozen tissues.32 This shows that the regular RT-PCR method for diagnostic purposes was as good as the qRT-PCR method. We also confirmed that IHC staining remains a useful and very reliable method. Moreover, it was the only method that could be used on the formalin-fixed, paraffin-embedded tissues stored long term. The results of immunohistochemistry as confirmed by molecular methods are still the most important source of information on fresh and formalin-fixed tissues.

References
1. Goscinski MA, Suo ZH, Nesland JM, Florenes VA, Giercksky KE. Dipeptidyl peptidase IV expression in cancer and stromal cells of human esophageal squamous cell carcinomas, adenocarcinomas and squamous cell carcinoma cell lines. APMIS 2008;116:823-31.
2. Chen WT, Kelly T. Seprase complexes in cellular invasiveness. Cancer Metastasis Rev 2003;22:259-69.
3. O’Brien P, O’Connor BF. Seprase: an overview of an important matrix serine protease. Biochim Biophys Acta 2008;1784:1130-45.
4. Keane FM, Nadvi NA, Yao TW, Gorrell MD. Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-alpha. FEBS J 2011;278:1316-32.
5. Roberts EW, Deonarine A, Jones JO, Denton AE, Feig C, Lyons SK, et al. Depletion of stromal cells expressing fibroblast activation protein-alpha from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med 2013;210:1137-51.
6. Keane FM, Yao TW, Seekl S, Gall MG, Chowdhury S, Poplawski SE, et al. Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs. FEBS Open Bio 2013;4:43-54.
7. Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 1999;274:36505-12.
8. Levy MT, McCaughan GW, Abbott CA, Park JE, Cunningham AM, Müller E, et al. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology 1999;29:1768-78.
9. Koczorowska MM, Tholen S, Bucher F, Lutz L, Kizhakkedathu JN, De Wever O, et al. Fibroblast activation protein-alpha, a stromal cell surface protease, shapes key features of cancer associated fibroblasts through proteome and degradome alterations. Mol Oncol 2016;10:40-58.
10. Kelly T. Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist Updat 2005;8:51-8.
11. Kelly T, Huang Y, Simms AE, Mazur A. Fibroblast activation protein-alpha: a key modulator of the microenvironment in multiple pathologies. Int Rev Cell Mol Biol 2012;297:83-116.
12. Ramirez-Montagut T, Blachere NE, Sviderskaya EV, Sviderskaya EV, Bennett DC, Rettig WJ, et al.
FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor. Oncogene 2004;23: 5435-46.

13. Monsky WL, Lin CY, Aoyama A, Kelly T, Akiyama SK, Mueller SC, et al. A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. Cancer Res 1994;54:5702-10.

14. Liu F, Qi L, Liu B, Liu J, Zhang H, Che D, et al. Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis. PLoS One 2015;10: e0116683.

15. Ha SY, Yeo SY, Xuan YH, Kim SH. The prognostic significance of cancer-associated fibroblasts in esophageal squamous cell carcinoma. PLoS One 2014;9:e99955.

16. Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther 2012;11:257-66.

17. Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade SR. Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. J Natl Cancer Inst 2012;104:1320-34.

18. Mueller MM, Fusenig NE. Friends or foes – bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4:839-49.

19. Brenness RM, Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol 2011;6:209-17.

20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Methods 2001;25:402-8.

21. Augoff K, Hryniewicz-Jankowska A, Tabola R, Czaplak L, Szalachowski P, Wierzbicki J, et al. Upregulated expression and activation of membrane-associated proteases in esophageal squamous cell carcinoma. Oncol Rep 2014;31:2820-6.

22. Tanaka T, Umeki K, Yamamoto I, Sakamoto F, Noguchi S, Ohtaki S, CD26 (dipeptidyl peptidase IV/DPP IV) as a novel molecular marker for differentiated thyroid carcinoma. Int J Cancer 1995;64:326-31.

23. Ikushima H, Munakata Y, Iwata S, Ohnuma K, Kobayashi S, Dang NH, et al. Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cell Immunol 2002;215: 106-10.

24. Kashyap MK, Marimuthu A, Kishore CJ, Peri S, Keerthikumar S, Prasad TS, et al. Genomewide mRNA profiling of esophageal squamous cell carcinoma for identification of cancer biomarkers. Cancer Biol Ther 2009;8:36-46.

25. von Ahlfen S, Missel A, Bendrat K, Schlumpberger M. Determinants of RNA quality from FFPE samples. PLoS One 2007; 2: e1261.

26. Yang W, Maqsodi B, Ma Y, Bui S, Crawford KL, McMaster GK, et al. Direct quantification of gene expression in homogenates of formalin-fixed, paraffin-embedded tissues. Biotechniques 2006;40:481-6.

27. Castiglione F, Rossi Degl’Innocenti D, Taddei A, Buccioni AM, Bechi P, Garbini F, et al. Real-time PCR analysis of RNA extracted from formalin-fixed and paraffin-embedded tissues: effects of the fixation on outcome reliability. Appl Immunohistochem Mol Morphol 2007; 15:338-42.

28. Marsh T, Pietras K, McAllister SS. Fibroblasts as architects of cancer pathogenesis. Biochim Biophys Acta 2013;1832:1070-8.

29. Mao Y, Keller ET, Garfield DH, Shen K, Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 2013;32: 303-15.

30. Cirri P, Chiarugi P. Cancer associated fibroblasts. the dark side of the coin. Am J Cancer Res 2011; 1: 482-97.

31. Huang Y, Simms AE, Mazur A, Wang S, León NR, Jones B, et al. Fibroblast activation protein-alpha promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions. Clin Exp Metastasis 2011; 28:567-79.

32. Wang XM, Yu DM, McCaughan GW, Gorrell MD. Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology 2005;42:935-45.

33. Bauer S, Jendro MC, Wadle A, Kleber S, Stenner F, Dinser R, et al. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther 2006; 8:R171.

34. Brokopp CE, Schoenauer R, Richards P, Bauer S, Lohmann C, Emmert MY, et al. Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheroma. Eur Heart J 2011;32: 2713-22.

35. Acharya PS, Zukas A, Chandan V, Katzenstein AL, Pure E. Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis. Hum Pathol 2006; 7:352-60.